{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T20:14:31Z","timestamp":1778184871317,"version":"3.51.4"},"reference-count":107,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Am Soc Clin Oncol Educ Book"],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>\n                      Mantle cell lymphoma (MCL) is a biologically and clinically heterogeneous B-cell malignancy with variable prognosis, ranging from indolent, asymptomatic forms to aggressive subtypes with early treatment failure. Contemporary management emphasizes risk-adapted strategies that integrate patient characteristics, clinical disease burden, and tumor biology. Prognostic tools such as the MCL International Prognostic Index (MIPI) and its biologically integrated variant (combined MIPI), alongside assessment of Ki-67 proliferation,\n                      <jats:italic toggle=\"yes\">TP53<\/jats:italic>\n                      status, and blastoid morphology, help guide treatment selection. In younger, fit patients, first-line therapy traditionally involves dose-intensified chemoimmunotherapy with high-dose cytarabine and autologous stem-cell transplantation (ASCT). The incorporation of Bruton tyrosine kinase inhibitors (BTKi), such as ibrutinib, into induction regimens has improved survival outcomes, with emerging evidence that may limit the use of ASCT to high-risk subsets. Maintenance therapy, particularly rituximab, remains crucial for durable disease control. In older or transplant-ineligible patients, bendamustine-rituximab remains a backbone therapy, with chemotherapy-free combinations incorporating BTKi, BCL2 inhibitors, and anti-CD20 antibodies offering effective, well-tolerated alternatives. High-risk patients, including those with\n                      <jats:italic toggle=\"yes\">TP53<\/jats:italic>\n                      mutations, may benefit from targeted triplet regimens or early cellular therapies. Relapsed\/refractory MCL is increasingly managed with covalent and noncovalent BTKi, BCL2 inhibitors, and T-cell\u2013redirecting therapies including chimeric antigen receptor T-cell therapy and bispecific antibodies. Ongoing trials are evaluating optimal sequencing and combination strategies to improve outcomes, particularly in high-risk and cBTKi-exposed patients. Overall, modern MCL management emphasizes individualized therapy based on biological risk, functional status, and treatment tolerability, with novel targeted and cellular approaches reshaping the frontline and relapsed treatment landscape.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1200\/edbk-26-517468","type":"journal-article","created":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T19:59:15Z","timestamp":1778183955000},"source":"Crossref","is-referenced-by-count":0,"title":["Modern Management of Mantle Cell Lymphoma"],"prefix":"10.1200","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-9279-0491","authenticated-orcid":false,"given":"Tobias","family":"Tix","sequence":"first","affiliation":[{"name":"Department of Medicine III, LMU Hospital, Munich, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anita","family":"Kumar","sequence":"additional","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toby A.","family":"Eyre","sequence":"additional","affiliation":[{"name":"Oxford University Hospitals NHS Foundation Trust, Churchill Cancer Center, Oxford, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Dreyling","sequence":"additional","affiliation":[{"name":"Department of Medicine III, LMU Hospital, Munich, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"233","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000712"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.hoc.2020.05.002"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI153283"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16317"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-06-095331"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.63.8387"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-08-737502"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-07-797019"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-04-779736"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V87.10.4302.bloodjournal87104302"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V87.8.3351.bloodjournal8783351"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1002\/hem3.70233"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-212973"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.02321"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-025-02787-0"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.18697"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.19.6121"},{"key":"e_1_3_2_19_2","first-page":"S230","article-title":"A prospective analysis of newly diagnosed mantle cell lymphoma: Predictors and survival of indolent disease","volume":"422334","author":"Mant S","year":"2024","unstructured":"Mant S, Naylor GU, Crosbie N, et al: A prospective analysis of newly diagnosed mantle cell lymphoma: Predictors and survival of indolent disease. EHA Libr Mant S 422334:S230, 2024","journal-title":"EHA Libr Mant S"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1002\/hem3.70080"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdg414"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx334"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx333"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14241"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01780"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)00184-3"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.7062"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(25)01432-1"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020008727"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-206778"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-194357"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023012424"},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2025-884"},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024025563"},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2025-3569"},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2025-888"},{"key":"e_1_3_2_37_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2025-664"},{"key":"e_1_3_2_38_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-25-00690"},{"key":"e_1_3_2_39_2","article-title":"Efficacy and safety of first-line ibrutinib plus venetoclax in patients with mantle cell lymphoma (MCL) who were older or had TP53 mutations in the SYMPATICO study","volume":"43","author":"Wang M","year":"2025","unstructured":"Wang M, Hoffmann MS, Wrobel T, et al: Efficacy and safety of first-line ibrutinib plus venetoclax in patients with mantle cell lymphoma (MCL) who were older or had TP53 mutations in the SYMPATICO study. J Clin Oncol 43, 2025 (suppl 16; abstr 7017)","journal-title":"J Clin Oncol"},{"key":"e_1_3_2_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(21)00195-2"},{"key":"e_1_3_2_41_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.02698"},{"key":"e_1_3_2_42_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-200735"},{"key":"e_1_3_2_43_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1701769"},{"key":"e_1_3_2_44_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-201441"},{"key":"e_1_3_2_45_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-023-01977-y"},{"key":"e_1_3_2_46_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-02-628792"},{"key":"e_1_3_2_47_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2025-883"},{"key":"e_1_3_2_48_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2025-666"},{"key":"e_1_3_2_49_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-206931"},{"key":"e_1_3_2_50_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1200920"},{"key":"e_1_3_2_51_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.01294"},{"key":"e_1_3_2_52_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61763-2"},{"key":"e_1_3_2_53_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-11-531327"},{"key":"e_1_3_2_54_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30685-5"},{"key":"e_1_3_2_55_2","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023009744"},{"key":"e_1_3_2_56_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.45.9842"},{"key":"e_1_3_2_57_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.01586"},{"key":"e_1_3_2_58_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.34.15_suppl.7503"},{"key":"e_1_3_2_59_2","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2025018527"},{"key":"e_1_3_2_60_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2201817"},{"key":"e_1_3_2_61_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024023962"},{"key":"e_1_3_2_62_2","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2018.205229"},{"key":"e_1_3_2_63_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-182942"},{"key":"e_1_3_2_64_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-200290"},{"key":"e_1_3_2_65_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1505237"},{"key":"e_1_3_2_66_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01797"},{"key":"e_1_3_2_67_2","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2020-0794"},{"key":"e_1_3_2_68_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-192939"},{"key":"e_1_3_2_69_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-181216"},{"key":"e_1_3_2_70_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1306220"},{"key":"e_1_3_2_71_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)33108-2"},{"key":"e_1_3_2_72_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021014162"},{"key":"e_1_3_2_73_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021013326"},{"key":"e_1_3_2_74_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-01013-3"},{"key":"e_1_3_2_75_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023023525"},{"key":"e_1_3_2_76_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022015560"},{"key":"e_1_3_2_77_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(24)00682-X"},{"key":"e_1_3_2_78_2","volume-title":"Presented at the EHA2025 Congress; June 12-15, 2025; Milan, Italy","author":"Tam CS","year":"2025","unstructured":"Tam CS, Lasica M, Soumerai JD, et al: Combination treatment with novel BCL2 inhibitor sonrotoclax (BGB-11417) + zanubrutinib induces high rate of complete remission for patients with relapsed\/refractory mantle cell lymphoma. Presented at the EHA2025 Congress; June 12-15, 2025; Milan, Italy, 2025"},{"key":"e_1_3_2_79_2","doi-asserted-by":"publisher","DOI":"10.1002\/hon.70093_OT03"},{"key":"e_1_3_2_80_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-22-3934"},{"key":"e_1_3_2_81_2","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.18519"},{"key":"e_1_3_2_82_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00224-5"},{"key":"e_1_3_2_83_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.00562"},{"key":"e_1_3_2_84_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2025-665"},{"key":"e_1_3_2_85_2","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2018.198812"},{"key":"e_1_3_2_86_2","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022008916"},{"key":"e_1_3_2_87_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2025-663"},{"key":"e_1_3_2_88_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01797"},{"key":"e_1_3_2_89_2","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2023.2268228"},{"key":"e_1_3_2_90_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.02370"},{"key":"e_1_3_2_91_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.02214"},{"key":"e_1_3_2_92_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-198018"},{"key":"e_1_3_2_93_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2025029734"},{"key":"e_1_3_2_94_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03084-6"},{"key":"e_1_3_2_95_2","doi-asserted-by":"publisher","DOI":"10.1002\/hem3.87"},{"key":"e_1_3_2_96_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-24-02158"},{"key":"e_1_3_2_97_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2025-662"},{"key":"e_1_3_2_98_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023021306"},{"key":"e_1_3_2_99_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.02470"},{"key":"e_1_3_2_100_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-174956"},{"key":"e_1_3_2_101_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_suppl.TPS7083"},{"key":"e_1_3_2_102_2","doi-asserted-by":"publisher","DOI":"10.1158\/2643-3230.BCD-24-0178"},{"key":"e_1_3_2_103_2","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.15721"},{"key":"e_1_3_2_104_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.49.2454"},{"key":"e_1_3_2_105_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mds054"},{"key":"e_1_3_2_106_2","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023012255"},{"key":"e_1_3_2_107_2","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2022-0976"},{"key":"e_1_3_2_108_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-173946"}],"container-title":["American Society of Clinical Oncology Educational Book"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/EDBK-26-517468","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T19:59:20Z","timestamp":1778183960000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/EDBK-26-517468"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":107,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["10.1200\/EDBK-26-517468"],"URL":"https:\/\/doi.org\/10.1200\/edbk-26-517468","relation":{},"ISSN":["1548-8748","1548-8756"],"issn-type":[{"value":"1548-8748","type":"print"},{"value":"1548-8756","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6]]},"article-number":"e517468"}}